Cargando…

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification

β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibitors to halt or delay the dysregulation of the amyloid-β pathway in Alzheimer’s disease (AD)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hampel, Harald, Lista, Simone, Vanmechelen, Eugeen, Zetterberg, Henrik, Giorgi, Filippo Sean, Galgani, Alessandro, Blennow, Kaj, Caraci, Filippo, Das, Brati, Yan, Riqiang, Vergallo, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566058/ https://www.ncbi.nlm.nih.gov/pubmed/33066807 http://dx.doi.org/10.1186/s13195-020-00686-3

Ejemplares similares

Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model
por: Hampel, Harald, et al.
Publicado: (2023)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study
por: Baldacci, Filippo, et al.
Publicado: (2020)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
por: Portelius, Erik, et al.
Publicado: (2010)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015)

γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing
por: Weber, Tobias A., et al.
Publicado: (2021)

State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
por: Hampel, Harald, et al.
Publicado: (2021)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Biomarkers for Alzheimer’s Disease (AD) and the Application of Precision Medicine
por: Lukiw, Walter J., et al.
Publicado: (2020)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
por: Hampel, Harald, et al.
Publicado: (2019)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method
por: Öhrfelt, Annika, et al.
Publicado: (2011)

Activity of Alzheimer’s γ-secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity
por: Yao, Annie Y., et al.
Publicado: (2020)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions
por: Hu, Xiangyou, et al.
Publicado: (2018)

Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance
por: Singh, Neeraj, et al.
Publicado: (2022)

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
por: Hölttä, Mikko, et al.
Publicado: (2016)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2017)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Zebrafish as an Innovative Tool for Epilepsy Modeling: State of the Art and Potential Future Directions
por: D’Amora, Marta, et al.
Publicado: (2023)

Bioinformatics tools and data resources for assay development of fluid protein biomarkers
por: Waury, Katharina, et al.
Publicado: (2022)

microRNA-Based Biomarkers in Alzheimer’s Disease (AD)
por: Zhao, Yuhai, et al.
Publicado: (2020)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease 
por: Hampel, Harald, et al.
Publicado: (2019)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
por: Hampel, Harald, et al.
Publicado: (2020)

The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline
por: Hampel, Harald, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_stni7kc271lp505h0bnq35p4kr